ZyVersa Therapeutics, Inc. - Warrants ZVSAW 深 沪
交易中 09-18 09:47:16 美东时间
0.07
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.07
- 总市值 0
- 52周最高 0.30
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.037
- 委 比 0.00%
- 总股本 --
- 历史最高 0.30
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.037
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression
ZyVersa Therapeutics is developing VAR 200, a Cholesterol Efflux Mediator™, to remove excess cholesterol and lipids from kidney cells, potentially mitigating renal disease progression. A phase 2a clinical trial for diabetic kidney disease (DKD) patients has begun, with preliminary results expected by Q4-2025. Preclinical studies suggest VAR 200 could reduce inflammation and oxidative stress in conditions like Alport Syndrome. The global kidney di...
09-03 11:55
ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression
糖尿病相关代谢问题导致肾脏脂质堆积，引发炎症和纤维化，进而造成肾功能损伤。研究证实，脂肪肾是慢性肾病（CKD）的独立风险因素，促进炎症和纤维化。ZyVersa公司的VAR 200药物通过直接移除肾脏中的多余脂质并调节相关转运蛋白，以缓解脂毒性。目前，针对糖尿病肾病的IIa期临床试验正在进行，未来计划扩展至其他肾脏疾病。全球肾脏疾病药物市场规模庞大，ZyVersa旨在通过缓解脂毒性，减少肾病进展，改善患者生活质量。
08-14 11:55
ZyVersa Therapeutics Q2 EPS $(0.46) Misses $(0.40) Estimate
ZyVersa Therapeutics (NASDAQ:ZVSA) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.40) by 15 percent. This is a 86.1 percent increase over losses of $(3.31) per share
08-13 21:06
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
ZyVersa Therapeutics reported Q2 2025 financial results with $2.05M raised since Q2, totaling $4.05M year-to-date. Key milestones include activation of the first clinical site for VAR 200's Phase 2a DKD trial, planned IND-enabling obesity study for IC 100, and a MJFF grant submission for Parkinson’s disease research. R&D expenses decreased 42.2% YoY to $0.4M, G&A expenses decreased 20.1% YoY to $1.6M, and net loss improved 20% to $2.2M. Cash on h...
08-13 13:00
ZyVersa Therapeutics Stock Approved for OTCQB Listing
The latest update is out from ZyVersa Therapeutics ( ($ZVSA) ). On July 25, 202...
07-28 20:19
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress
ZyVersa Therapeutics' CEO, Stephen C. Glover, updates shareholders on mid-year developments, highlighting $12 million in financing and progress in kidney and inflammatory disease treatments. Their VAR 200 drug targets kidney diseases, with Phase 2a trials in diabetic kidney disease expected to report preliminary data by Q4-2025. IC 100, an inflammasome inhibitor, is advancing for obesity and neurodegenerative diseases, with preclinical studies se...
07-21 11:55
ZyVersa Therapeutics Faces Nasdaq Delisting, Plans Pink Market Move
An announcement from ZyVersa Therapeutics ( ($ZVSA) ) is now available. On July...
07-17 00:58
ZyVersa Therapeutics Enters Warrant Exercise Agreement
The latest announcement is out from ZyVersa Therapeutics ( ($ZVSA) ). On July 8...
07-10 04:53
ZyVersa Therapeutics Provides Regulatory And Product Support For FDA-Authorized Emergency Compassionate Use Of Cholesterol Efflux Mediator VAR 200 In ApoCII Amyloidosis Patient
ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into the urine
07-08 19:54
ZyVersa Therapeutics Secures $10M Equity Purchase Agreement
ZyVersa Therapeutics ( ($ZVSA) ) has provided an announcement. On June 24, 2025...
06-25 21:31
